HOME >> BIOLOGY >> NEWS
Subtle signs can help predict Huntington's disease early

ST. PAUL, Minn Subtle signs can help doctors predict that a person will develop Huntington's disease in the next few years, according to a study published in the May 15, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology. Huntington's disease is a genetic disorder that affects movement, thinking, and some aspects of personality. There is no treatment or cure for the disease.

"These results will help us understand how and who will develop Huntington's, which is important information as potential treatments are developed," said study author Jane S. Paulsen, PhD, of the University of Iowa Roy J. and Lucille A. Carver College of Medicine in Iowa City. "Ideally, treatments will target at-risk people at or before the earliest stages of the disease, before they have any problems with thinking or movement."

The study involved 218 people in North America, Europe and Australia considered at risk for Huntington's disease because they had at least one parent with the disease. If a parent has the disease, there is a 50-percent chance that the child will develop the disease.

The participants were healthy at the beginning of the study, with normal scores on movement tests or minimal signs of movement problems. They were then followed for up to 4.5 years. Those with minimal motor problems at the beginning of the study were nearly five times more likely to be diagnosed with the disease a year and a half later than those who had no movement problems initially. They were 3.5 times more likely to be diagnosed with the disease after three years.

Researchers also tested cognitive abilities. For a verbal fluency test, they were given a letter of the alphabet and 60 seconds to say as many words as they could starting with that letter. They were also tested on how quickly they could combine thinking and movement, or "psychomotor speed," with a memory and writing task. Those who performed worse on the psychomotor
'"/>

Contact: Angela Babb
ababb@aan.com
651-695-2789
American Academy of Neurology
14-May-2007


Page: 1 2

Related biology news :

1. Subtle changes in normal genes implicated in breast cancer
2. Rove beetles act as warning signs for clear-cutting consequences
3. Delft University of Technology designs language development toy for autistic children
4. Medieval Islamic designs reveal breakthrough in tiled pattern-making
5. Simple diagnostic test detects genetic signs of lung cancer in a patients sputum
6. MIT designs portable lab on a chip
7. Engineer designs system to put wastewater to work
8. Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes
9. Damaged Iraq marshes show renewed signs of life
10. Harvard Medical signs agreement with Merck to develop potential therapy for macular degeneration
11. Why are letters and other human visual signs shaped the way that they are?

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Subtle signs can help predict Huntington disease early

(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
(Date:12/15/2014)... & PETACH TIKVAH, Israel ... (NASDAQ: BCLI ), a leading developer of ... that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded ... Israel,s Office of the Chief Scientist (OCS).  ... in receipt of grant support from the Office of ...
(Date:12/15/2014)... NEW YORK , Dec. 15, 2014  GlassesOff ... Yuval Bar-Gil as an independent director of ... was founder of AeroScout and served as its CEO ... Decker in 2012, a $240 million transaction. Recognized as ... under Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID ...
(Date:12/15/2014)... 15, 2014  Ascendis Pharma A/S, a biotechnology ... address significant unmet medical needs, today announced positive ... pediatric study to evaluate once-weekly TransCon Growth Hormone ... This interim analysis consists of 25 patients, representing ... the study, completing all six months of treatment. ...
(Date:12/13/2014)... - MaRS and Virgin Unite Canada, the non-profit foundation of ... to support Canadian entrepreneurs tackling social and environmental challenges. Today, ... the MaRS Centre to announce the new partnership, which includes ... fund has $1 million in seed capital provided by Virgin ... Social Innovation Foundation, founded by Alison Lawton . ...
Breaking Biology Technology:BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
Cached News: